Droxia

Ovarian Neoplasms, Thrombocythemia, Essential, Anemia, Sickle Cell + 4 more
Treatment
2 FDA approvals
20 Active Studies for Droxia

What is Droxia

HydroxyureaThe Generic name of this drug
Treatment SummaryMethotrexate is a medication that prevents cancer cells from growing and dividing by preventing them from making DNA.
Hydroxyureais the brand name
image of different drug pills on a surface
Droxia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Hydroxyurea
Hydroxyurea
1998
25

Approved as Treatment by the FDA

Hydroxyurea, also known as Hydroxyurea, is approved by the FDA for 2 uses which include inoperable Ovarian cancer and Ovarian Neoplasms .
inoperable Ovarian cancer
Ovarian Neoplasms

Effectiveness

How Droxia Affects PatientsHydroxyurea has been found to have a positive effect when used alongside cisplatin, a chemotherapy drug. It was especially effective when taken four hours before the cisplatin in treating human lung cancer, and was also found to work well against murine lung cancer.
How Droxia works in the bodyHydroxyurea works by stopping cells from making DNA. It does this by entering the cell and disabling a molecule called ribonucleotide reductase, which is used to make DNA. This action leads to cell death, as well as inhibiting the repair of damage to DNA caused by radiation or other chemicals. Finally, hydroxyurea increases the level of fetal hemoglobin, reducing the risk of crises in people with sickle cell anemia.

When to interrupt dosage

The recommended dosage of Droxia is contingent upon the diagnosed condition, including Myeloid Leukemia, Hypereosinophilic Syndrome (HES) and Thrombocythemia, Essential. The measure of dosage fluctuates as per the strategy of delivery featured in the table below.
Condition
Dosage
Administration
Thrombocythemia, Essential
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Sickle Cell Crisis
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Polycythemia Vera
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Hypereosinophilic Syndrome
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Ovarian Neoplasms
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Anemia, Sickle Cell
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Meningioma
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral

Warnings

There are 20 known major drug interactions with Droxia.
Common Droxia Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Acteoside.
Droxia Toxicity & Overdose RiskHydroxyurea is toxic to mice and rats in doses of 7330mg/kg and 5760mg/kg respectively. It may cause birth defects in experimental animals, but has not been linked to any adverse effects in humans. There have also been reports of hydroxyurea causing genetic mutations in both animals and humans.
image of a doctor in a lab doing drug, clinical research

Droxia Novel Uses: Which Conditions Have a Clinical Trial Featuring Droxia?

A total of 63 active clinical trials are examining the potential of Droxia to treat Myeloid Leukemia, Polycythemia Vera (PV) and Inoperable Ovarian Cancer.
Condition
Clinical Trials
Trial Phases
Thrombocythemia, Essential
25 Actively Recruiting
Phase 2, Phase 1, Phase 3
Sickle Cell Crisis
1 Actively Recruiting
Not Applicable
Anemia, Sickle Cell
1 Actively Recruiting
Not Applicable
Ovarian Neoplasms
0 Actively Recruiting
Hypereosinophilic Syndrome
0 Actively Recruiting
Polycythemia Vera
0 Actively Recruiting
Meningioma
0 Actively Recruiting

Droxia Reviews: What are patients saying about Droxia?

5Patient Review
11/24/2013
Droxia for Sickle Cell Anemia
This treatment has been working well for me. I go months without a crisis, whereas before I would have several in the span of just a couple months. The only downside is that I have to take pills every day, which can be annoying.
5Patient Review
8/5/2010
Droxia for Sickle Cell Anemia
2Patient Review
10/12/2011
Droxia for Sickle Cell Anemia
my son has been taking this medication for a little over 3 years now, and unfortunately he's been extremely sick the entire time. Some of the issues he's experienced are severe stomach pain, paleness, fluid retention and possible infection in his left hip, as well as tingling and pain in both arms and legs. In my opinion, this pill is doing more harm than good.

Patient Q&A Section about droxia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do you take droxia?

"The dosage is based on your medical condition, response to treatment, and other medications you may be taking. Be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Droxia is taken by mouth, with or without food, once daily. The dosage is based on the patient's medical condition, response to treatment, and other medications the patient is taking. The medication guide should be read before taking Droxia, and any questions should be directed to the doctor or pharmacist. All products used by the patient, including prescription and nonprescription drugs, as well as herbal products, should be reported to the doctor or pharmacist."

Answered by AI

How much does droxia cost?

"Droxia is a medication used to treat cancer. The average retail price for Droxia is $69.71. You can save 20% on the retail price of Droxia by comparing prices at different pharmacies."

Answered by AI

What is droxia used for?

"Hydroxyurea is a medication used to reduce the frequency of painful crises and reduce the need for blood transfusions in adults and children 2 years of age and older with sickle cell anemia. Sickle cell anemia is an inherited blood disorder in which the red blood cells are abnormally shaped and cannot bring enough oxygen to the body's tissues."

Answered by AI

What is the drug Hydrea used for?

"Hydroxyurea is a medication used to prevent painful episodes and reduce the need for blood transfusions in patients with sickle cell anemia. Hydroxyurea works by making red blood cells more flexible. A prescription from a doctor is required to obtain hydroxyurea."

Answered by AI

Clinical Trials for Droxia

Image of City of Hope Comprehensive Cancer Center LAO in Duarte, United States.

ASTX727 + Iadademstat for Myeloproliferative Disorders

18+
All Sexes
Duarte, CA
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with iadademstat may be more effective than ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative MPNs.
Phase 2
Recruiting
City of Hope Comprehensive Cancer Center LAO (+6 Sites)Anand A Patel
Image of Ruttenberg Treatment Center in New York, United States.

Methotrexate for Myeloproliferative Disorders

18+
All Sexes
New York, NY
Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor. If MTX proves to be safe and tolerable with a signal of clinical activity, this could have a significant benefit to patients with MPNs. Beyond the potential benefit of adding a type 2 JAK inhibitor to current therapy, this could signal the need to study MTX in MPNs further as a monotherapy. Discovering MTX as safe and clinically effective in MPNs could be profound on both a public health and global health scale for patients who are uninsured and cannot afford more expensive novel JAK inhibitors, or for those in countries where JAK inhibitors are not available. Accordingly, the research team deems it reasonable and prudent to assess the safety and efficacy of MTX in addition to current therapy for patients with MPN. The research team will evaluate patients for spleen responses, symptom responses, and cytologic responses. Correlative data will evaluate pharmacokinetic and disease modifying activity of MTX in MPNs to inform future clinical trials.
Phase 2
Recruiting
Ruttenberg Treatment CenterJohn Mascarenhas
Have you considered Droxia clinical trials? We made a collection of clinical trials featuring Droxia, we think they might fit your search criteria.Go to Trials
Image of University of Michigan ( Site 6000) in Ann Arbor, United States.

Bomedemstat for Blood Disorders

18+
All Sexes
Ann Arbor, MI
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.
Phase 3
Recruiting
University of Michigan ( Site 6000) (+3 Sites)Medical DirectorMerck Sharp & Dohme LLC
Have you considered Droxia clinical trials? We made a collection of clinical trials featuring Droxia, we think they might fit your search criteria.Go to Trials
Image of Children's Wisconsin in Milwaukee, United States.

Enhanced Emergency Care for Sickle Cell Crisis

< 65
All Sexes
Milwaukee, WI
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.
Recruiting
Has No Placebo
Children's WisconsinDavid Brousseau, MD, MS
Have you considered Droxia clinical trials? We made a collection of clinical trials featuring Droxia, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security